Comparative Analysis of Genetically Modified Dendritic Cells and Tumor Cells as Therapeutic Cancer Vaccines
暂无分享,去创建一个
[1] J. Allison,et al. Combination Immunotherapy of B16 Melanoma Using Anti–Cytotoxic T Lymphocyte–Associated Antigen 4 (Ctla-4) and Granulocyte/Macrophage Colony-Stimulating Factor (Gm-Csf)-Producing Vaccines Induces Rejection of Subcutaneous and Metastatic Tumors Accompanied by Autoimmune Depigmentation , 1999, The Journal of experimental medicine.
[2] T. Luger,et al. Generation of tumor immunity by bone marrow-derived dendritic cells correlates with dendritic cell maturation stage. , 1999, Journal of immunology.
[3] L. Kanz,et al. Generation of Functional Human Dendritic Cells From Adherent Peripheral Blood Monocytes by CD40 Ligation in the Absence of Granulocyte-Macrophage Colony-Stimulating Factor , 1998 .
[4] S. Ma,et al. Lymphotactin gene-modified bone marrow dendritic cells act as more potent adjuvants for peptide delivery to induce specific antitumor immunity. , 1998, Journal of immunology.
[5] D. Neuberg,et al. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[6] L. Timares,et al. Quantitative analysis of the immunopotency of genetically transfected dendritic cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[7] J. Mulé,et al. Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[8] J. Geiger,et al. The Role of Tumor Necrosis Factor α in Modulating the Quantity of Peripheral Blood-Derived, Cytokine-Driven Human Dendritic Cells and Its Role in Enhancing the Quality of Dendritic Cell Function in Presenting Soluble Antigens to CD4+ T Cells In Vitro , 1998 .
[9] Polly Matzinger,et al. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell , 1998, Nature.
[10] Richard A. Flavell,et al. Help for cytotoxic-T-cell responses is mediated by CD40 signalling , 1998, Nature.
[11] Stephen P. Schoenberger,et al. T-cell help for cytotoxic T lymphocytes is mediated by CD40–CD40L interactions , 1998, Nature.
[12] P. Lollini,et al. Interleukin 12 gene therapy of MHC-negative murine melanoma metastases. , 1998, Cancer research.
[13] B. Dörken,et al. Retroviral interleukin-7 gene transfer into human dendritic cells enhances T cell activation , 1998, Gene Therapy.
[14] L. Kanz,et al. Generation of functional human dendritic cells from adherent peripheral blood monocytes by CD40 ligation in the absence of granulocyte-macrophage colony-stimulating factor. , 1998, Blood.
[15] H. Klocker,et al. Prostaglandin E2 and Tumor Necrosis Factor ␣ Cooperate to Activate Human Dendritic Cells: Synergistic Activation of Interleukin 12 Production , 1997 .
[16] I. Kimber,et al. Langerhans cells require signals from both tumour necrosis factor‐α and interleukin‐1β for migration , 1997, Immunology.
[17] S. Rafii,et al. Dendritic Cells Genetically Modified with an Adenovirus Vector Encoding the cDNA for a Model Antigen Induce Protective and Therapeutic Antitumor Immunity , 1997, The Journal of experimental medicine.
[18] S. Rosenberg,et al. Dendritic Cells Retrovirally Transduced with a Model Antigen Gene Are Therapeutically Effective against Established Pulmonary Metastases , 1997, The Journal of experimental medicine.
[19] R. Steinman,et al. Dendritic Cells as Adjuvants for Immune-mediated Resistance to Tumors , 1997, The Journal of experimental medicine.
[20] D. Bigner,et al. Bone Marrow–generated Dendritic Cells Pulsed with Tumor Extracts or Tumor RNA Induce Antitumor Immunity against Central Nervous System Tumors , 1997, The Journal of experimental medicine.
[21] D. Kufe,et al. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells , 1997, Nature Medicine.
[22] M. Bevan,et al. Virus-mediated delivery of antigenic epitopes into dendritic cells as a means to induce CTL. , 1997, Journal of immunology.
[23] J. Banchereau,et al. CD40 ligation counteracts Fas-induced apoptosis of human dendritic cells. , 1997, International immunology.
[24] M. Kitamura,et al. Construction of adenovirus vectors through Cre-lox recombination , 1997, Journal of virology.
[25] J. Banchereau,et al. CD40 Ligation on Human Cord Blood CD34+Hematopoietic Progenitors Induces Their Proliferation and Differentiation into Functional Dendritic Cells , 1997, The Journal of experimental medicine.
[26] R. Mulligan,et al. Bioactive murine and human interleukin-12 fusion proteins which retain antitumor activity in vivo , 1997, Nature Biotechnology.
[27] R. Mulligan,et al. A stable human-derived packaging cell line for production of high titer retrovirus/vesicular stomatitis virus G pseudotypes. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[28] R. Mulligan,et al. Induction of Antigen-Specific Tumor Immunity by Genetic and Cellular Vaccines against MAGE: Enhanced Tumor Protection by Coexpression of Granulocyte-Macrophage Colony-Stimulating Factor and B7-1 , 1996, Molecular medicine.
[29] E. Gilboa,et al. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo , 1996, The Journal of experimental medicine.
[30] A. Lanzavecchia,et al. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation , 1996, The Journal of experimental medicine.
[31] M. Colombo,et al. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo , 1996, The Journal of experimental medicine.
[32] J. Mayordomo,et al. Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity , 1996, The Journal of experimental medicine.
[33] L. Zitvogel,et al. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines , 1996, The Journal of experimental medicine.
[34] L. Zitvogel,et al. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity , 1995, Nature Medicine.
[35] L. Zitvogel,et al. Cancer immunotherapy of established tumors with IL-12. Effective delivery by genetically engineered fibroblasts. , 1995, Journal of immunology.
[36] C Danieli,et al. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products , 1995, The Journal of experimental medicine.
[37] G. Pauli,et al. Spontaneous apoptosis of dendritic cells is efficiently inhibited by TRAP (CD40‐ligand) and TNF‐α, but strongly enhanced by interleukin‐10 , 1995, European journal of immunology.
[38] G. Dranoff,et al. Gene transfer as cancer therapy. , 1995, Advances in immunology.
[39] J. Banchereau,et al. Activation of human dendritic cells through CD40 cross-linking , 1994, The Journal of experimental medicine.
[40] F. Sallusto,et al. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha , 1994, The Journal of experimental medicine.
[41] Yao-Tseng Chen,et al. Identification of the MAGE-1 gene product by monoclonal and polyclonal antibodies. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[42] Simon C Watkins,et al. Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo. , 1994, Cancer research.
[43] E. Jaffee,et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[44] R. Steinman,et al. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor , 1992, The Journal of experimental medicine.
[45] P. Chomez,et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. , 1991, Science.
[46] T. Blankenstein,et al. Interleukin 7 induces CD4+ T cell-dependent tumor rejection , 1991, The Journal of experimental medicine.
[47] D. Pardoll,et al. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. , 1991, Science.
[48] K. Tracey,et al. Long-term inhibition of tumor growth by tumor necrosis factor in the absence of cachexia or T-cell immunity. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[49] B. Vogelstein,et al. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response , 1990, Cell.
[50] S. Miyatake,et al. Exogenous expression of mouse interferon gamma cDNA in mouse neuroblastoma C1300 cells results in reduced tumorigenicity by augmented anti-tumor immunity. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[51] P. Leder,et al. Murine interleukin-4 displays potent anti-tumor activity in vivo , 1989, Cell.